SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cantel Medical Corp – ‘8-K’ for 3/2/21

On:  Tuesday, 3/2/21, at 5:06pm ET   ·   For:  3/2/21   ·   Accession #:  1104659-21-30840   ·   File #:  1-31337

Previous ‘8-K’:  ‘8-K’ on / for 1/12/21   ·   Next:  ‘8-K’ on / for 3/9/21   ·   Latest:  ‘8-K’ on 4/1/21 for 3/31/21   ·   5 References:   

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/02/21  Cantel Medical Corp               8-K:9       3/02/21   11:389K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     33K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     93K 
 7: R1          Cover                                               HTML     47K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- tm218182d1_8k_htm                   XML     14K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- cmd-20210302_lab                      XML     96K 
 5: EX-101.PRE  XBRL Presentations -- cmd-20210302_pre               XML     64K 
 3: EX-101.SCH  XBRL Schema -- cmd-20210302                          XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001104659-21-030840-xbrl      Zip     25K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0000019446  i false 0000019446 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant To Section 13 Or 15(d) of The Securities Exchange Act of 1934

 

Date of earliest event reported:  i March 2, 2021

 

 i CANTEL MEDICAL CORP.

(Exact Name of Registrant as Specified in its Charter)

 

 i Delaware    i 001-31337    i 22-1760285

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 i 150 Clove Road,  i Little Falls,  i New Jersey    i 07424   ( i 973)  i 890-7220
(Address of Principal Executive Offices)   (Zip code)  

(Registrant’s telephone number,

including area code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i xWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 i Common Stock    i CMD    i New York Stock Exchange
(Title of each class)   (Trading Symbol)  

(Name of each exchange on which

registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  i ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 C: 

 

 

Explanatory Note

 

This Current Report on Form 8-K is being filed by Cantel Medical Corp. (the “Company”) for the purpose of incorporating it by reference into the registration statement on Form S-4 to be filed by STERIS plc (“STERIS”), as it may be amended or supplemented, in connection with the pending merger transaction between the Company and STERIS.

 

Important Information for Investors and Shareholders

 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger between STERIS and Cantel, STERIS will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will include a proxy statement of Cantel that also constitutes a prospectus of STERIS. The definitive proxy statement/prospectus will be delivered to shareholders of Cantel. INVESTORS AND SECURITY HOLDERS OF STERIS AND CANTEL ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive proxy statement/prospectus (when available) and other documents filed with the SEC by STERIS and Cantel through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by STERIS will be available free of charge on STERIS’s internet website at www.STERIS.com or by contacting STERIS’s Investor Relations Department at (440) 392-7245. Copies of the documents filed with the SEC by Cantel will be available free of charge on Cantel’s internet website at www.cantelmedical.com or by contacting Cantel’s Investor Relations Department at (763) 553-3341.

 

Participants in the Merger Solicitation

 

STERIS, Cantel, their respective directors and certain of their respective executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Cantel shareholders in connection with the proposed merger will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of Cantel is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on November 18, 2020 and certain of its Current Reports on Form 8-K. Information about the directors and executive officers of STERIS is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on June 5, 2020 and certain of its Current Reports on Form 8-K. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus filed with the above-referenced registration statement on Form S-4 and other relevant materials to be filed with the SEC when they become available.

 

Item 9.01. Financial Statements and Exhibits

 

(a) Financial Statements of Business to be Acquired.

 

The unaudited condensed consolidated financial statements of Dental Holding, LLC and Subsidiaries as of September 30, 2019, and for the nine months ended September 30, 2019 and 2018 and the notes related thereto, are filed as Exhibit 99.1 hereto.

 

(b) Exhibits.

 

Exhibit No.   Description of Exhibit
     
99.1   Unaudited condensed consolidated financial statements of Dental Holding, LLC and Subsidiaries as of September 30, 2019 and for the nine months ending September 30, 2019 and 2018, and the notes related thereto.
     
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CANTEL MEDICAL CORP.
  (Registrant)
     
     
Date: March 2, 2021 By: /s/ Brian R. Capone
    Brian R. Capone
    Senior Vice President, Corporate Controller and Chief Accounting Officer

 

 C: 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:3/2/21425
11/18/20DEF 14A
6/5/20
9/30/19
9/30/18
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/21  Cantel Medical Corp               DEFM14A                1:5.7M                                   Broadridge Fin’l So… Inc
 4/01/21  STERIS plc                        424B3                  1:3.7M                                   Broadridge Fin’l So… Inc
 3/26/21  STERIS plc                        424B5                  1:1.4M                                   Donnelley … Solutions/FA
 3/24/21  STERIS plc                        424B5                  1:1.4M                                   Donnelley … Solutions/FA
 3/23/21  STERIS plc                        S-3ASR      3/23/21   23:3.1M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001104659-21-030840   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 18, 11:09:47.0am ET